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Abstract
Introduction
Many people at high risk for sexually transmitted infections (STIs), e.g., men who have sex
with men (MSM), are not optimally reached by current sexual health care systems with test-
ing. To facilitate testing by home-based sampling or sampling in outreach setting we evalu-
ated dried blood spots (DBS), a method for self-collected blood sampling for serological
screening of HIV, hepatitis B (HBV) and syphilis. The aims of this study were to assess the
acceptability and feasibility of self-collected DBS and to compare the test results for screen-
ing of HIV, HBV and syphilis from DBS with blood drawn by venous puncture.
Methods
DBS were collected from men who have sex with men (MSM), visiting the STI clinic of the
public health service South Limburg (n = 183) and HIV positive and HBV positive patients
(n = 34), visiting the outpatient clinics of the Maastricht University Medical Centre in the
period January 2012–April 2015. The 93 first participating MSM visiting the STI clinic were
asked to fill in a questionnaire about the feasibility and acceptability about self-collection of
DBS in a setting without going to a health care facility and were asked to collect the DBS
themselves. Serological screening tests for HIV (HIV combi PT, Roche), HBV (HBsAg,
Roche) and syphilis (Treponema pallidum Ig, Biokit 3.0) were performed on DBS and on
blood drawn by venous puncture, which was routinely taken for screening.
Results
In total 217 participants were included in the study with a median age of 40 years (range
between 17–80). Of MSM 84% agreed that it was clear and easy to do the finger-prick, while
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53% agreed that it was clear and easy to apply the blood onto the DBS card. Also, 80% of
MSM would use the bloodspot test again. In 91% (198) of DBS, sufficient material was col-
lected to perform the three tests. No difference was observed in DBS quality between self-
collected DBS and health care worker collected DBS. For HIV (n = 195 DBS-serum pairs)
sensitivity and specificity were 100%. For HBV the sensitivity for HBsAg (n = 202) was 90%
and specificity was 99%. For syphilis (n = 191) the sensitivity of the DBS was 93% with a
specificity of 99%. Analysis of the DBS of HIV positive participants (n = 38) did show similar
test performance for HBV and syphilis as in HIV negatives.
Conclusion
DBS is an acceptable self-sampling method for MSM, as there was no difference in DBS
quality in self-collected and health care worker collected DBS. Test performance, i.e., its
high sensitivity (>90%) and specificity (>99%) measures show that DBS is a valid alternative
for venous blood puncture. Especially when DBS is combined with home-collected sampling
for Chlamydia trachomatis and Neisseria gonorrhoeae, complete STI screening can be
done in outreach setting and/or home-collected sampling in MSM.
Introduction
For the control of sexually transmitted infections (STI) timely testing and adequate treatment
strategies are essential to prevent adverse health outcomes and reduce or halt transmission.
Still many infected people remain untested and untreated [1–3]. This may be because they do
not attend care or because they are not adequately tested when in care. For example, while STI
clinic guidelines recommend regular testing in men who have sex with men (MSM), the reality
is that MSM are infrequently tested, only partially tested or not tested at all [4–6]. Even, HIV
positive MSM may remain hidden to care, because they are not visiting regular (STI) care ser-
vices and/or STI care is often considered beyond the focus of the HIV practitioner [6, 7]. Fur-
ther, MSM who contact their GP may not be completely tested, such as would have been the
case when they were tested according to STI clinic guidelines (i.e. on human immunodefi-
ciency virus (HIV), syphilis, Hepatitis B virus (HBV), and anorectal and urogenital and/or oro-
pharyngeal Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) [8].
To increase STI testing beyond regular STI care, many target group specific interventions
have been set up to increase testing behavior in key populations like MSM. These include the
use of web based outreach strategies combined with home-collection of screening samples for
testing [9–11]. It has been shown that self-sampling can be a feasible and effective alternative
for key populations that are currently not visiting STI clinics or accessing other regular health
care. Self-sampling especially introduced in STI screening programs can be a valuable addition
to current STI control [10, 12–16].
Till now self-based testing interventions were mainly focused on CT and NG testing in het-
erosexual individuals as these samples have been shown to be as easy, acceptable and valid
compared to samples taken by a health care provider [12, 13]. However, for screening of HIV,
HBV and syphilis, a care provider still needs to draw a venous blood sample hampering home-
sampling. Self-taken blood sampling procedures are hardly available in routine STI care set-
tings in industrialized countries. An alternative self-sampling blood test could positively
impact efficiency of STI control in MSM. Also in outreach screening and in hard to reach
DBS for screening of HIV, Hepatitis B and Syphilis
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populations in partner testing or enhanced screening of potentially affected contacts during
outbreaks for e.g. syphilis self-sampling may be of added value.
A method for self-collected sampling of blood samples, more commonly used in developing
countries, is sampling by dried blood spots (DBS) with a finger prick. Blood droplets are
absorbed on a filter paper, which subsequently can be sent to a laboratory by regular mail [17–
19].
Previous studies showed that DBS results for HIV, HBV and syphilis are as reliable as
venous blood puncture [17–24]. Most studies are, however, performed in settings different
from ours, e.g. hospital setting instead of self-collected sampling, different climatic circum-
stances, so that transport conditions are different.
In this study we assessed the acceptability and feasibility of self-collection of DBS in MSM
visiting an STI clinic and we evaluated the performance of DBS for serological screening of
HIV, HBV and syphilis compared to blood drawn by venipuncture in our regular routine set-
ting of our STI clinic and HIV and hepatitis outpatient clinic of our hospital. A valid and
acceptable alternative for serum could likely have great impact to reach hidden MSM with test-
ing as an addition to regular care.
Methods
Study populations
DBS were collected from MSM, visiting the STI clinic of the public health service South Lim-
burg (PHS) and among HIV and/or HBV infected patients, visiting the outpatient clinics for
HIV and/or hepatitis of the Maastricht University Medical Centre (MUMC) in the period Jan-
uary 2012—April 2015. In total 217 individuals participated; 183 visited the STI clinic and 34
the outpatient clinics. The participants of the outpatient clinics were included in the study to
purposefully increase the number of HIV and HBV positive DBS samples.
Questionnaire about feasibility and acceptability
The first 93 (51%) MSM who participated in de DBS study, visiting the STI clinic were asked
to fill in a questionnaire about the feasibility and acceptability about self-collection of DBS.
These individuals were asked to collect the DBS themselves to imitate the sampling situation at
home as much as possible. They were provided an instruction scheme with several steps
depicted by icons and a clear picture of the DBS card with the 5 circles (cross section 1.5 cm)
for sampling. Three completely filled spots were needed to perform 3 tests. The DBS from the
other participants were taken by health-care providers to compare self-sampling with sampling
by a health care provider. The questionnaire included questions whether they (completely)
agreed with statements (5-items) on the experience of self-collection, the instructions for use,
the future use of DBS, comparing different care settings and social acceptance.
Routine diagnostics for HIV, Treponema pallidum and HBV
HIV Ag/Ab, Treponema Ig and HBsAg are essential tests to screen for active infections and
used for this purpose in current care. Although the national policy is vaccinating all MSM for
HBV not all MSM are fully vaccinated yet and therefore HBsAg screening is included in this
study.
Screening for HIV infection is done with a fourth generation screening HIV Ag/Ab test (HIV
combi PT, Roche, Basel, Switzerland). The result of the HIV Ag/Ab test gave an index value,
which was interpreted as follows:< 0.9 is negative,> = 0.9 and<1.1 is grey zone and> = 1.1 is
DBS for screening of HIV, Hepatitis B and Syphilis
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positive. Grey zone and positive screening tests were confirmed by an immunoblot (MP diag-
nostics, Santa Anna, California, USA).
The algorithm for syphilis screening on serum was as follows: For seronegative individuals
screening was performed with an anti-Treponemal antibody (T. pallidum Ig) test (Treponema
pallidum, Biokit 3.0, Barcelona, Spain). Borderline or positive T. pallidum Ig tests were con-
firmed by TPPA (Fujirebio Diagnostic inc. Malvern, PA, USA) and FTA-abs (Trepo-spot IF,
Biomerieux, Lyon, France) for confirmation of the syphilis infection and RPR (RPR reditest,
Biokit, Barcelona, Spain) to determine stage and activity of infection. Discrepant combination
of results were sent to a reference laboratory (National Institute for Public Health and the
Environment) for confirmation with immunoblot. The result of the T. pallidum Ig test was
indicated as an index value, which was interpreted as follows: <0.9 was negative, > = 0.9 and
<1.1was grey zone and> = 1.1 was positive.
In routine setting screening for HBV on serum was done with testing HBsAg for active HBV
infection (HBsAg II, Roche, Basel, Switzerland). In case of a positive HBsAg test, anti HBc, anti-
HBs, HBeAg, and anti-HBe (anti-HBc, anti-HBs II, HBeAg, anti-HBe, Roche, Basel, Switzer-
land) were additionally determined in serum. If necessary a HBsAg confirmation test was used
(Biomerieux, Lyon, France). The result of the HBsAg gave an index value, which was inter-
preted as follows: For HBsAg< 0.9 was negative,> = 0.9 and<1.1 was grey zone and> = 1.1
was positive.
The DBS results were compared with the results from routine diagnostic test algorithms.
This means that (low) positive screening tests in serum that could not be confirmed in the con-
firmation assays were interpreted as negative. Thus the conclusive result based on both regular
screening test and confirmatory test (gold standard) were used to compare with DBS, which
were tested with the screening tests only (i.e. HIV Ag/Ab, Treponema Ig and HBsAg). For con-
firmatory tests following positive screening in DBS a secondary sample (i.e. venous blood)
would be required.
Elution from DBS
DBS were drawn from the 3rd or 4th finger by puncture with a lancet. For this study a card with
5 spots with a diameter of 15 mm should be filled with blood. After taking the DBS the cards
were air-dried for at least 10 minutes. The cards were transported to the laboratory within 48
hrs. in sealed bags.
The cards were kept at 4˚C until analysis. Analysis was done within 5 days. Eight mm discs
were punched and placed into a microtube. Discs for HIV Ag/Ab and HBsAg were eluted in
PBS– 0.5% tween buffer and for T. pallidum Ig discs were eluted in diluent of the assay (Biokit
3.0, Barcelona, Spain). Two discs were placed in 250 μl buffer and incubated for 1 hour on a
rotation table. After centrifuging the eluate was directly used for the tests.
Medical ethical approval
The medical ethics committee of the Maastricht University Medical Centre (Maastricht, the
Netherlands) approved the study (12-4-040). All participants were asked prior to voluntary
participation to give their written informed consent.
Statistical analysis
Descriptive statistics were performed using IBM1 SPSS Statistics (V.23.0.0, IBM, Somers,
New York, USA). Chi-square test was used for comparing self-collected and health care pro-
vider collected DBS and coefficient of determination (R2) were used for comparing analytical
indexes of the test results of DBS and sera.
DBS for screening of HIV, Hepatitis B and Syphilis
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Results
Study participants
The median age of the participants (n = 217) was 40 years with a range between 17–80 years.
The majority of the participants (202/217, 93%) were of male sex. From the STI clinic 183
MSM participated and from the out-patient clinic 19 men and 15 women.
The DBS contained variable amounts of blood per spot and variable numbers of blood
spots were filled (up to five). In 198 (91.2%) of participants 3 spots were sufficiently filled to
perform 3 tests. From 5 and 1 participants, respectively 2 and 1 test(s) could be performed due
to low amount of blood. Thirteen DBS cards could not be used for testing because the blood
volume on the DBS was insufficient for testing. There was no statistically significant difference
in self-sampling (n = 88) or sampling by a health care provider (n = 129) in the number of
tests that could be performed (Chi2 P = 0.73).
Feasibility and acceptability
Ninety three MSM participants filled in the questionnaire on feasibility and acceptability
(Table 1). Notable was that the majority of men agreed that it was clear (84%) and easy (86%)
to do the finger-prick, while lower percentages agreed that it was clear and easy to apply the
blood onto the card. Also, the majority of men would use the bloodspot test again, but only
half mentioned that sending DBS over the postal mail would be fine. Few of these men, who
Table 1. Acceptance of DBS testing and attitudes towards future use in 93 MSM undergoing DBS test
and attending an STI clinic for regular STI care.
Instructions and experience of use (completely)
agree *
It is clear how to do the finger-prick 84.2% (n = 80)
It is easy to do the finger-prick 86.3% (n = 82)
How to apply the blood on the card is clear 69.5% (n = 66)
To apply the blood on the card is easy 53.7 (n = 51)
It is unpleasant to do the finger-prick 26.3% (n = 25)
Future use
A bloodspot test is a good initiative 57.9% (n = 55)
I would do the bloodspot test again 80.0% (n = 76)
To send my bloodspot over the postal mail is fine with me 50.5% (48)
A test result by email or text message is acceptable 89.5% (85)
Comparing care-settings
I prefer a finger-prick over blood drawing by a clinic nurse 8.4% (n = 8)
I prefer to do an STI test at home than to come to the STI clinic 15.8% (n = 15)
A personal talk with a professional nurse is more important to me than able to do a
test at home
81.1% (n = 77)
Social acceptance
I think that my friends find an STI test with a bloodspot by the Internet a good
initiative
49.5% (n = 47)
I think that my friends would use the blood spot test at their home 41.1% (n = 39)
I think my friends would prefer to do an STI test at home than to come to the STI
clinic
47.4% (n = 45)
Acceptance of DBS testing and attitudes towards future use in 93 MSM undergoing DBS test and attending
an STI clinic for regular STI care.
*score 1 and 2 on likert scale 1–5 (completely agree to completely disagree)
https://doi.org/10.1371/journal.pone.0186722.t001
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came for a clinic visit and then were confronted with a DBS, stated that they would prefer DBS
over clinic visit. Slightly less than half of the men thought that their friends would use DBS and
might also prefer home-based sampling over a clinic visit.
Comparison of DBS and routine diagnostics
For validity of DBS analysis we tested 195 DBS-serum pairs for HIV Ag/Ab, 191 for T. palli-
dum Ig and 202 DBS-serum pairs for HBsAg. HIV Ag/Ab showed a 100% sensitivity and speci-
ficity (Table 2). For T. pallidum Ig the sensitivity was 90% with specificity of 99%. The
sensitivity for HBsAg was respectively 90% with specificity of 99%.
Discrepancy analysis
In total 7 (1.2%) out of 588 DBS-serum pairs tested showed a different result in DBS and
serum. No discrepant results were observed for HIV Ag/Ab. For T. pallidum Ig 3 infections
were false negative in DBS and 2 borderline false positive in DBS. For HBsAg, 2 discrepant
results were found; one false positive in DBS and one false negative in DBS. (Table 3).
Index values in DBS and serum
Index values for HIV Ag/Ab, T. pallidum Ig and HBsAg were compared between DBS and
serum (Fig 1). For HIV Ag/Ab and HBsAg a clear distinction between positive and negative
results was shown (R2 were respectively, 0.92 and 0.90 for HIV Ag/Ab and HBsAg). For T. pal-
lidum Ig this distinction was less clear, since the number of false negatives in DBS were higher,
compared to the HIV and HBsAg index values (see previous paragraph) (R2 was 0.75 for T.
pallidum Ig).
Table 2. Test results of DBS-serum pairs of the validation study.
Test No. of
samples
tested
No. samples positive
in DBS and serum
No. samples negative
in DBS and serum
Sensi-
tivity
95%CI; upper and
lower limit of
sensitivity
Speci-
ficity
95% CI; upper and
lower limit of specificity
HIV Ag/Ab 195 38 157 100% 81%-100% 100% 97%-100%
T.
pallidum
Ig
191 26 160 90% 72%-97% 99% 95%-100%
HBsAg 202 17 183 90% 71%-100% 99% 97%-100%
Number of DBS-serum pairs tested and test results of the validation study (95%CI–95% confidence interval).
https://doi.org/10.1371/journal.pone.0186722.t002
Table 3. Analysis of discrepant results in DBS and serum.
Test No. of samples
tested
No. of discrepant
results
Discrepancy in Conclusion
T. pallidum
Ig
191 3 DBS−/ serum + false negative in DBS: confirmation of lues infection with positive TPPA
and FTA-Abs
2 DBS + / serum − borderline false positive in DBS; serum was negative
HBsAg 202 1 DBS−/ serum + HBsAg = 2.2 in serum: chronic HBV carrier in reconvalescence phase
1 DBS + / serum − false positive HBsAg = 1.17 index in DBS
Analysis of discrepant results in DBS and serum.
https://doi.org/10.1371/journal.pone.0186722.t003
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HIV positive participants
In total 38 HIV positive participants were included. Test performance appeared similar in HIV
positives with sensitivities of 92% and 100% respectively for T. pallidum Ig and HBsAg and
specificities of 100% for the both tests, although confidence intervals were wide (Table 4).
Discussion
This study shows that DBS as method for sampling is a valid alternative for venous blood
puncture with high sensitivity (>90%) and specificity (>99%) for HIV Ag/Ab, Treponema pal-
lidum Ig and HBsAg. DBS is also found acceptable in MSM in our study. To a large extent
DBS proved to be likely feasible in routine use since overall 91% of the DBS was adequately
taken to perform the three screening tests. Also, there was no difference in the quality of DBS
taken by self-sampling compared to DBS taken by a health care provider This makes self-col-
lected sampling with DBS (in combination with additional genital and anorectal CT and NG
testing) a feasible approach to reach part of the hidden MSM. It could therefore be a valuable
addition to regular care and also could be used for outreach settings [16, 25].
This study is not without limitations. In 70% of the participants who filled in the questionnaire
the method was clear and they would do DBS again. Nevertheless, acceptability was measured in
a selection of MSM (possibly overestimating acceptance) who attended the STI clinic (possibly
underestimation of acceptance as they already came to a clinic and already had received care by a
professional). Although we included patients from the HIV and hepatitis out-patient clinics to
artificially increase the number of positives analyses, the numbers were still rather small (between
17 and 38), possibly limiting the precision in the sensitivities estimated. Other studies also studied
cohorts with various numbers of positives (between 10 to 204) [19, 20, 22, 24, 26]. Further, we
have small numbers for subgroup analysis, such as analyses by HIV status.
The quality of DBS may be subject to interobserver bias because the DBS were visually
screened before preparation of the eluate. However, we expect this to be a small bias and there-
fore of minor influence on our results.
Fig 1. Scatterplots of the index values measured in DBS and serum. Scatterplots of the index values
measured in DBS and serum. 2a. shows the log transformed results for HIV Ag/Ab, 2b. the results for T.
pallidum Ig 2c. the log transformed results for HBsAg.
https://doi.org/10.1371/journal.pone.0186722.g001
Table 4. Subgroup analysis of DBS-serum pairs in HIV positive participants.
Test No. of
samples
tested
No. of samples
positive in DBS and
serum
No. of samples
negative in DBS and
serum
Sensi-
tivity
95% CI; upper and
lower limit of
sensitivity
Speci-
ficity
95% CI; upper and
lower limit of
specificity
T.
pallidum
Ig
36 12 24 92% 74–100% 100% 79%–100%
HBsAg 38 1 37 100% 3%–100% 100% 91%–100%
Subgroup analysis of DBS-serum pairs in HIV positive participants (95% CI–95% confidence interval).
https://doi.org/10.1371/journal.pone.0186722.t004
DBS for screening of HIV, Hepatitis B and Syphilis
PLOS ONE | https://doi.org/10.1371/journal.pone.0186722 October 20, 2017 7 / 11
HIV Ag/Ab in DBS showed a sensitivity and specificity of 100%. Comparison of the index
values in DBS and serum show a good correlation. Similar results were found in other studies
showing sensitivities of 100% and specificities of 99.5%-100% in DBS despite the fact that dif-
ferent elution protocols and screening assays were used in these studies [19, 20, 22, 23].
T. pallidum Ig in DBS in this study showed a sensitivity of 90% with a specificity of 99%.
Smit et al. found a sensitivity (94%) with EIA syphilis screening [26]. They found, however, a
low specificity of 50%, which may be due to increased non-specific binding in the assay,
because they used a longer incubation time.
HBsAg showed acceptable sensitivity of 90% and specificity of 99%. Other studies showed
sensitivities of 96–98% and specificities of 100% [17, 20, 22, 24]. Our study showed a slightly
lower sensitivity because one low positive HBsAg (index of 2.2) was missed in DBS. This
serum was from a chronic HBV carrier in the period of seroconversion from positive to nega-
tive. These and other data indicate that the lower detection limit is increased in DBS and low
positive levels of HBsAg levels in serum may be missed in DBS [22]. However, this should be
no problem in routine screening for active HBV infection (either acute or chronic HBV),
because it has been shown that HBsAg levels in chronically HBV infected persons are usually
above 100 IU/ml, which can be detected by DBS [27–29]. This is in line with the results of our
other HBsAg positive participants (Fig 1).
Several factors should be taken into account to implement DBS as method for sampling.
Successful implementation would for example be dependent on whether users understand
how to apply the blood samples on the paper and how willing they would be to send the DBS
by postal mail. The actual application in care however still needs to be assessed, such as in our
ongoing intervention study called PacMan. Although there is room for improving the instruc-
tions for taking DBS, the results in this study with respect to the acceptability and feasibility
was overall adequate. In 91% of the DBS 3 tests could be performed. One study with a response
rate of 90% showed that for HIV screening with DBS 99% of the DBS were adequately taken
by self-collection [30]. Yet, in our study 9% were inadequately taken DBS and instructions can
be optimized to improve this further.
To be able to implement DBS in routine setting it is also important that storage and trans-
port conditions do not influence the test results. In routine use it will take up to 3 days before
DBS will arrive at the laboratory when DBS are home-collected and sent to the laboratory by
regular mail. For HIV Ag/Ab and HBsAg storage conditions have been assessed for stability at
room temperature up to 200 days [18, 19, 24]. DBS were stable at room temperature for at least
one week until 4 weeks [18, 19, 24]. For implementation in routine setting the storage at room
temperature does not exceed one week, if DBS are directly sent to the laboratory. Thus, it is
not expected that sending DBS by regular mail would harm the test results and it is the most
convenient way of transportation of DBS to the laboratory.
In conclusion, DBS as method for self-sampling at home is a valid and likely acceptable
alternative for venous blood puncture for STI screening in MSM. It was also feasible to iuse in
addition to in routine STI clinic care. The next step is to implement DBS as method for home-
collected sampling in combination with self-collection of swabs and/or urine for CT and NG
screening in order to better reach the hidden MSM with STI testing and treatment.
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